Q-omics provides the consensus-scored BTBD6P1 profile across patient tissues and cancer cell-line models. BTBD6P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BTBD6P1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, BTBD6P1 RNA expression shows 15,018 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, THCA, and LSCC as cancer lineages where BTBD6P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD6P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD6P1 survival associations across molecular data types. BTBD6P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD6P1 RNA expression–survival associations across cancer types. High BTBD6P1 expression shows favorable associations in HNSC, ESCA, LUAD, UCS, SKCM and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BTBD6P1 RNA expression.
This table summarizes BTBD6P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BTBD6P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD6P1 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in UCEC, CHOL and BRCA. The THCA box plot shows higher BTBD6P1 RNA expression in normal versus tumor tissue (log2 FC = −0.620, t-test p < 0.001).
This table shows molecular features associated with BTBD6P1 in patient tissues and cancer cell lines. In patient samples, BTBD6P1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
